BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36715792)

  • 21. The aftermath of hip fragility fractures - are we missing out on osteoporosis treatment?".
    Costa R; Romano J; Moreira A; Dantas D; Ribeiro P; Agre M; Correia J
    Acta Reumatol Port; 2021; 46(4):328-332. PubMed ID: 34962247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fragility non-hip fracture patients are at risk.
    Gosch M; Druml T; Nicholas JA; Hoffmann-Weltin Y; Roth T; Zegg M; Blauth M; Kammerlander C
    Arch Orthop Trauma Surg; 2015 Jan; 135(1):69-77. PubMed ID: 25412880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality following fragility hip fracture in China: a record linkage study.
    Hua Y; Li Y; Zhou J; Fan L; Huang F; Wu Z; Xue H; Yang B; Chen P; Rui Y; Tian Y; Moayyeri A; Libanati C; Du W
    Arch Osteoporos; 2023 Jul; 18(1):105. PubMed ID: 37498371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand.
    Mahaisavariya C; Vanitcharoenkul E; Kitcharanant N; Chotiyarnwong P; Unnanuntana A
    BMC Geriatr; 2023 Feb; 23(1):70. PubMed ID: 36737708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary prevention of osteoporosis in non-neck of femur fragility fractures: is it value for money? A retrospective, prospective and cross-sectional cohort study.
    Mettyas T; Carpenter C
    J Orthop Surg Res; 2013 Dec; 8():44. PubMed ID: 24289492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019.
    Agarwal AR; Cohen JS; Jorgensen A; Thakkar SC; Srikumaran U; Golladay GJ
    Osteoporos Int; 2023 Feb; 34(2):379-385. PubMed ID: 36462054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
    Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
    Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should patients with exceptional longevity be treated for osteoporosis after a hip fracture?
    Barceló M; Casademont J; Mascaró J; Gich I; Torres OH
    Age Ageing; 2024 Jun; 53(6):. PubMed ID: 38899445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly.
    Tran T; Bliuc D; Pham HM; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser SM; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    J Bone Miner Res; 2020 Oct; 35(10):1923-1934. PubMed ID: 32460361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is a reasonable rate for specific osteoporosis drug therapy in older fragility fracture patients?
    Gosch M; Bail HJ; Grueninger S; Stumpf U; Kammerlander C; Wicklein S
    Arch Osteoporos; 2020 Feb; 15(1):20. PubMed ID: 32088765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
    Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
    Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are we treating osteoporotic fractures of the hip adequately? A Middle Eastern cohort study.
    Venugopal Menon K; Al Harthy HHS; Al Habsi KSK; Al Ruzaiqi HAH
    Arch Osteoporos; 2018 Jan; 13(1):6. PubMed ID: 29368309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample.
    Bawa HS; Weick J; Dirschl DR
    J Bone Joint Surg Am; 2015 Oct; 97(19):1555-62. PubMed ID: 26446962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario.
    Brown JP; Adachi JD; Schemitsch E; Tarride JE; Brown V; Bell A; Reiner M; Oliveira T; Motsepe-Ditshego P; Burke N; Slatkovska L
    BMC Musculoskelet Disord; 2021 Jan; 22(1):105. PubMed ID: 33485305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoporosis Care Gap After Hip Fracture - Worse With Low Healthcare Access and Quality.
    Galli S; Weiss D; Beck A; Scerpella T
    J Clin Densitom; 2022; 25(3):424-431. PubMed ID: 34696980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The American Orthopaedic Association's Own the Bone® database: a national quality improvement project for the treatment of bone health in fragility fracture patients.
    Carlson BC; Robinson WA; Wanderman NR; Nassr AN; Huddleston PM; Yaszemski MJ; Currier BL; Jeray KJ; Kirk KL; Bunta AD; Murphy S; Patel B; Watkins CM; Sietsema DL; Edwards BJ; Tosi LL; Anderson PA; Freedman BA
    Osteoporos Int; 2018 Sep; 29(9):2101-2109. PubMed ID: 29858634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and circumstances of falls in hip fractures.
    Iolascon G; Gravina P; Luciano F; Palladino C; Gimigliano F
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S133-5. PubMed ID: 24046036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-fracture care gap: a retrospective population-based analysis of Hong Kong from 2009 to 2012.
    Cheung MY; Ho AW; Wong SH
    Hong Kong Med J; 2018 Dec; 24(6):579-583. PubMed ID: 30449735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.